|
US 10,376,519 B2 |
|
Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation |
Jay Copeland Strum, Hillsborough, NC (US); John Emerson Bisi, Apex, NC (US); Patrick Joseph Roberts, Durham, NC (US); Ricky D. Gaston, Kalamazoo, MI (US); and Robert C. Gadwood, Portage, MI (US) |
Assigned to G1 Therapeutics, Inc., Research Triangle Park, NC (US) |
Filed by G1 Therapeutics, Inc., Research Triangle Park, NC (US) |
Filed on Jul. 31, 2017, as Appl. No. 15/665,071. |
Application 15/665,071 is a continuation of application No. 14/690,180, filed on Apr. 17, 2015, granted, now 9,717,735, issued on Aug. 1, 2017. |
Claims priority of provisional application 61/980,895, filed on Apr. 17, 2014. |
Claims priority of provisional application 61/980,939, filed on Apr. 17, 2014. |
Claims priority of provisional application 61/980,918, filed on Apr. 17, 2014. |
Claims priority of provisional application 61/980,883, filed on Apr. 17, 2014. |
Prior Publication US 2017/0333440 A1, Nov. 23, 2017 |
Int. Cl. C07D 487/14 (2006.01); C07D 487/20 (2006.01); C07D 471/20 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61K 31/527 (2006.01); A61K 31/519 (2006.01) |